RHÖN-KLINIKUM Aktiengesellschaft (OTCMKTS:RKAGY) & Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Financial Comparison

RHÖN-KLINIKUM Aktiengesellschaft (OTCMKTS:RKAGY) and Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings.

Earnings & Valuation

This table compares RHÖN-KLINIKUM Aktiengesellschaft and Fresenius Medical Care AG & Co. KGaA”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RHÖN-KLINIKUM Aktiengesellschaft	N/A	N/A	N/A	$4.50	1.81
Fresenius Medical Care AG & Co. KGaA	$22.20 billion	0.57	$1.11 billion	$1.93	12.31

Fresenius Medical Care AG & Co. KGaA has higher revenue and earnings than RHÖN-KLINIKUM Aktiengesellschaft. RHÖN-KLINIKUM Aktiengesellschaft is trading at a lower price-to-earnings ratio than Fresenius Medical Care AG & Co. KGaA, indicating that it is currently the more affordable of the two stocks.

Dividends

RHÖN-KLINIKUM Aktiengesellschaft pays an annual dividend of $0.08 per share and has a dividend yield of 1.0%. Fresenius Medical Care AG & Co. KGaA pays an annual dividend of $0.61 per share and has a dividend yield of 2.6%. RHÖN-KLINIKUM Aktiengesellschaft pays out 1.8% of its earnings in the form of a dividend. Fresenius Medical Care AG & Co. KGaA pays out 31.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for RHÖN-KLINIKUM Aktiengesellschaft and Fresenius Medical Care AG & Co. KGaA, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RHÖN-KLINIKUM Aktiengesellschaft	0	0	0	0	0.00
Fresenius Medical Care AG & Co. KGaA	5	6	0	0	1.55

Fresenius Medical Care AG & Co. KGaA has a consensus target price of $23.57, indicating a potential downside of 0.77%. Given Fresenius Medical Care AG & Co. KGaA’s stronger consensus rating and higher probable upside, analysts clearly believe Fresenius Medical Care AG & Co. KGaA is more favorable than RHÖN-KLINIKUM Aktiengesellschaft.

Profitability

This table compares RHÖN-KLINIKUM Aktiengesellschaft and Fresenius Medical Care AG & Co. KGaA’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
RHÖN-KLINIKUM Aktiengesellschaft	N/A	N/A	N/A
Fresenius Medical Care AG & Co. KGaA	4.83%	9.28%	4.16%

Institutional & Insider Ownership

0.2% of RHÖN-KLINIKUM Aktiengesellschaft shares are owned by institutional investors. Comparatively, 8.4% of Fresenius Medical Care AG & Co. KGaA shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Fresenius Medical Care AG & Co. KGaA beats RHÖN-KLINIKUM Aktiengesellschaft on 9 of the 11 factors compared between the two stocks.

About RHÖN-KLINIKUM Aktiengesellschaft

RHÖN-KLINIKUM Aktiengesellschaft, together with its subsidiaries, offers in-patient, semi-patient, and outpatient healthcare services in Germany. It also operates acute hospitals, medical care centers, and rehabilitation hospitals. The company was founded in 1973 and is based in Bad Neustadt an der Saale, Germany.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. Fresenius Medical Care AG was incorporated in 1996 and is headquartered in Bad Homburg, Germany.